SUMMARY The expression of carcinoembryonic antigen (CEA) was evaluated by immunoperoxidase staining with two anti-CEA monoclonal antibodies in normal, chronically inflamed, and malignant pancreatic tissue. Positive staining was not observed in normal specimens. In pancreatic cancer the expression of CEA was related to the degree of differentiation of the tumour. Positive staining was also observed in chronic pancreatitis.
Carcinoma of the pancreas is often diagnosed by exclusion despite advances in computed tomography and ultrasonography. The early results of tumour localisation with radiolabelled antibodies to tumour associated antigens suggest that this technique may be complementary to the established methods of investigation.1 2 Indeed, it is in conditions such as carcinoma. of the pancreas that immunolocalisation may realise its full potential.
The well established association of carcinoembryonic antigen (CEA) with carcinoma of the pancreas suggests that it may be a suitable target for radiolabelled antibodies. Reports have described high values both in the sera3 4 and the pancreatic juice of patients with pancreatic cancer.5 6 Few studies, however have described the tissue distribution of CEA,7 8 which is of great importance if it is to be regarded as a target for immunolocalisation. Studies have also described high values both in the sera and the juice of patients with chronic pancreatitis.5 9 to This apparent lack of specificity of CEA for malignancy has resulted in its limited clinical role as a marker for pancreatic cancer. The development of monoclonal antibodies"1 has produced agents that have the potential to identify specific tumour antigens or antigenic determinants and so differentiate malignant from benign tissues.
In this study two monoclonal anti-CEA antibodies were evaluated immunohistochemically to determine whether the staining pattern for CEA could differentiate normal, chronically inflamed, and maligAccepted for publication 6 February 1986 nant pancreatic tissue and to investigate antigenic heterogeneity in pancreatic tumours.
Material and methods

TISSUE SECTIONS
Serial tissue sections 5 gm thick were cut from formalin fixed paraffin embedded specimens of chronic pancreatitis (n = 10) and carcinoma of the pancreas (n = 30). Most of these specimens were obtained as biopsies at operation and had been stored as paraffin embedded blocks for up to 12 months. The degree of 11-285-14 (Table 3 ). This did not seem to be an absolute relation, however, as negative staining with 11-285-14 was also detected in one of the well differentiated tumours, as was positive staining in one of the undifferentiated growths. Nevertheless, with both antibodies negative staining was most common in either anaplastic or poorly differentiated tumours, reflecting the correspondingly low potential for glandular formation and CEA expression.
Positive staining with either antibody was observed in six of 10 (60%) specimens of chronic pancreatitis. The actual number of cells that stained, however, was In a recent study of several different monoclonal anti-CEA and anti-NCA antibodies in panreatic cancer Tsutsumi et al'9 showed that staining patterns vary in frozen and paraffin embedded tissues. In particular, NCA, or CEA related substances with antigenic determinants common to NCA, were more readily identifiable in frozen sections of normal tissues. In this study we examined only paraffin embedded sections. Although formalin fixation and paraffin embedding may have interfered with the binding of 111-359-6 to NCA in normal pancreatic cells it is more likely that 11-359-6 recognises a different epitope to that detected by the antibodies reported by Tsutsumi et al.
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These results have shown that the epitope recognised by 11-359-6 is less often expressed by pancreatic cancer cells than that recognised by 11-285-14. Nevertheless, neither antibody can be claimed to be specific for CEA in pancreatic cancer, as each reacted positively with cells in 60% of samples of chronic pancreatitis. This cross reactivity suggests that these antibodies would not be of value in discriminating between chronic pancreatitis and carcinoma in in vivo localisation studies. Such studies would also be limited because of the small number of cells in most tumours that express the antigens.
This study has shown a higher rate of CEA expression in pancreatic cancer cells than has been previously reported. The epitopes of CEA that were detected, however, were also present in chronic pancreatitic cells, indicating that they are not tumour specific. Further monoclonal antibodies to CEA or to other tumour associated antigens, such as pancreatic oncofetal antigen,20 should be evaluated in pancreatic cancer to determine whether a tumour specific agent can be identified which differentiates cancer from chronic pancreatitis.
